SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX)
NBIX 146.85-0.3%Nov 12 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (746)5/30/2001 9:57:14 PM
From: Spekulatius  Read Replies (3) of 1834
 
Rick, IJ, Miljenko - There is nothing wrong with NBIX but recovery came to fast, IMHO. When the market goes downhill, NBIX shareprice will come down hard. The same is true for most other biotechs, short term they are simply liquidity driven. I wait for most of them to reenter earth atmosphere before buying in again.

Miljenko's remark that diabetes drug could be worth 1B$ market cap is interesting. Seems very high for me, considering the stage the drug is in. Also NRGN has a CRF1 program, even though its preclinical and behind NBIX.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News